



The Government Bioscience Grant (GBG) report is produced each month and is available at www.biosciencefunding.com.
 For more information on non-dilutive government funding opportunities, please contact (216) 658-3995 or www.G2Gconsulting.com.

Government Bioscience Grant (GBG) Report – June 2015

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Eligibility	Link
			NEURAL SYSTEMS				
	DoD FY15 Spinal Cord Injury Clinical Trial Award (USAMRAA)	W81XW H-15-SCIRP-CTA	The SCIRP Clinical Trial Award supports human subjects research with the potential to have a major impact on the treatment or management of SCI and its consequences in military Service members, Veterans, or other individuals. Funding from this award mechanism must support a clinical trial and may not be used for preclinical research studies. The FY15 SCIRP encourages applications that specifically address one or more of the following areas: 1. Pre-hospital, en route care, and early hospital management of SCI 2. Development, validation, and timing of promising interventions to address consequences of SCI and to improve recovery, including, but not limited to: Bladder, bowel, and autonomic dysfunction; Cardiometabolic dysfunction; Neuropathic pain and sensory dysfunction; Pressure ulcers; Respiratory dysfunction; Sexual dysfunction 3. Identification and validation of best practices in SCI care including but not limited to: Critical care interventions; Interventions for musculoskeletal health; Rehabilitation interventions; Surgical interventions; Psychosocial and behavioral interventions in military/Veteran populations.	Pre-application: 7/13/15 Submission: 10/14/15	Award Ceiling: \$2,000,000 Estimated Total Program Funding: \$9,600,000	Unrestricted	http://cdmrp.army.mil/funding/pa/15scirpta_pa.pdf

DoD FY15 Spinal Cord Injury Investigator-Initiated Research Award	W81XW H-15-SCIRP-IIRA	The SCIRP Investigator-Initiated Research Award is intended to support studies that have the potential to make an important contribution to SCI research, patient care, and/or quality of life; applicants are encouraged to address one of the SCIRP focus areas listed in the program announcement. Applications must include preliminary and/or published data that is relevant to SCI and the proposed research project. Investigator-Initiated Research Award applications may focus on any phase of research from basic through translational, including preclinical studies in animal models or human subjects, as well as correlative studies associated with an existing clinical trial.	Pre-application: 7/13/15 Submission: 10/14/15	Award Ceiling: \$500,000 Estimated Total Program Funding: \$7,200,000	Unrestricted	http://cdmrp.army.mil/funding/pa/15scirpira_pa.pdf	
DoD FY15 Spinal Cord Injury Translational Research Award Department of Defense (USAMRAA)	W81XW H-15-SCIRP-TRA	The FY15 SCIRP challenges the scientific community to design innovative research that will foster new directions for and address neglected issues in the field of SCI-focused research. Applications from investigators within the military Services, and applications involving multidisciplinary collaborations among academia, industry, the military Services, the Department of Veterans Affairs (VA), and other Federal Government agencies are highly encouraged. Though the SCIRP supports groundbreaking research, all projects must demonstrate solid scientific rationale. The SCIRP Translational Research Award mechanism was first offered in FY12. Since then, 30 Translational Research Award applications have been received, and 7 have been recommended for funding.	Pre-application: 7/13/15 Submission: 10/14/15	Award Ceiling: \$1,250,000 Estimated Total Program Funding: \$6,800,000	Unrestricted	http://cdmrp.army.mil/funding/pa/15scirpttra_pa.pdf	
		PHARMACEUTICALS					
Improving Immunization Collaboration Among Pharmacists and Other Healthcare	CDC-RFA-IP15-1504PPH F15	The purpose of this FOA is to demonstrate successful models of collaboration between pharmacists and other healthcare providers in a way that ensures up-to-date vaccination status of their shared patients. Better collaboration between pharmacists and other healthcare providers is needed because of the increasing interdependence of pharmacists and other clinicians. Pharmacists are providing a higher percentage of immunization than in	7/27/15	Award Floor: \$500,000 per project period Award Ceiling:	Unrestricted	https://www.acf.hhs.gov/hhs/grantsforecast/index.cfm?switch=grant.view&gff_grants	

	Provider (HHS, CDC)		previous years. With that comes the need to strengthen their collaboration with their patients' other healthcare providers.		\$800,000 per project period		forecastInfoID=100000585
			WORKFORCE DEVELOPMENT				
	DoD Prostate Cancer Physician Research Training Award	W81XW H-15-PCRP-PRTA	The PCRP Physician Research Training Award mechanism was first offered in FY03. Since then, 175 Physician Research Training Award applications have been received, and 75 have been recommended for funding. The Physician Research Training Award supports a mentored training experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research. This award emphasizes equally the quality of both the research and the training proposed. The trainee is considered the Principal Investigator (PI) of the application. All applications for the Physician Research Training Award are to be written by the PI, with appropriate direction from the mentor(s). The PI must demonstrate a commitment to a career as an investigator at the forefront of prostate cancer research and clinical practice; however, the PI is not required to have previous prostate cancer research experience.	Pre-proposal: 6/30/15 Full submission: 8/13/15	Est. Total Program Funding: \$4,160,000 Annual Cap: \$130,000 per year of the 3-4 year performance Award Floor: \$0 Expected number of Awards: 5	Unrestricted	http://cdmrp.army.mil/funding/pa/15pcrpp_rta_pa.pdf
	DoD Prostate Cancer Postdoctoral Training Award	W81XW H-15-PCRP-PTA	The PCRP Postdoctoral Training Award mechanism was first offered as the Postdoctoral Traineeship Award in FY99 and was incorporated into the Prostate Cancer Training Award in FY06-FY10. In total, 1,575 Postdoctoral Training Award applications have been received, and 482 have been recommended for funding. The Postdoctoral Training Award supports prostate cancer research training opportunities for recent doctoral graduates. These awards primarily provide salary support for the Principal Investigator (PI); the postdoctoral trainee is considered the PI of the application. The PI must exhibit strong potential for, and commitment to, pursuing a career as an investigator at the forefront of prostate cancer research; however, the PI is not required to have previous prostate cancer research experience.	Pre-proposal: 6/20/15 Full submission: 8/13/15	Est. Total Program Funding: \$5,000,000 Award Ceiling: \$0 Award Floor: \$0 Expected number of Awards: 25	Unrestricted	http://cdmrp.army.mil/funding/pa/15pcrpp_rta_pa.pdf

			CANCER				
	DoD Prostate Cancer Dr. Barbara Terry-Koroma Health Disparity Research Award	W81XW H-15-PCRPH-DRA	The mission of the FY15 PCRPH is to find and fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of men experiencing the impact of the disease. Specifically, the PCRPH seeks to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; multidisciplinary, synergistic research; translational studies to support the fluid transfer of knowledge between bedside and bench; research on patient survivorship and quality of life; the next generation of prostate cancer investigators through mentored research; and research on disparities in the incidence and mortality of prostate cancer.	Pre-application: 7/16/15 Submission: 9/24/15	Award Ceiling: \$600,000 Estimated Program Funding: \$5,800,000	Unrestricted	http://cdmrp.army.mil/funding/pa/15pcrphdra_pa.pdf
	DoD Prostate Cancer Idea Development Award	W81XW H-15-PCRPH-IDA	The Idea Development Award supports new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRPH mission. Although groundbreaking research often involves a degree of risk, applications should be based on a sound scientific rationale that is established through logical reasoning and/or critical review and analysis of the literature. Due to this award's emphasis on innovation, the presentation of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required. Research deemed innovative may represent a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative.	Pre-application: 6/25 Full Submission: 9/24/15	Est. Total Program Funding: \$31,700,000 Expected number of Awards: 46	Unrestricted	http://cdmrp.army.mil/funding/pa/15pcrphida_pa.pdf

	DoD Lung Cancer Concept Award	W81XW H-15- LCRP-CA	The Concept Award supports the exploration of a highly innovative new concept or untested theory that addresses an important problem relevant to lung cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of lung cancer or develop an innovative and novel course of investigation.	Pre-application: 7/28/15 Full submission: 8/11/15	Est. Total Program Funding: \$2,080,000 Expected number of awards: 13	Unrestricted	http://cdmrp.army.mil/funding/pa/15lcrpca_pa.pdf
			DIABETES				
	NIDDK Centers for Diabetes Translational Health (HHS, NIH)	RFA-DK-15-003	This Funding Opportunity Announcement (FOA) invites applications for Centers for Diabetes Translation Research (CDTR). The CDTRs support and enhance diabetes type II translation research (e.g., bedside to practice and the community and dissemination and implementation). The purpose of this Centers program is to enhance the innovation and multidisciplinary nature of diabetes translation research. An emphasis on research to reduce diabetes-related health disparities is encouraged. CDTRs are based on the core concept, whereby shared resources aimed at fostering productivity, synergy, and new research ideas among the funded investigators are supported in a cost-effective manner.	11/23/15	\$3 million is available in FY16 for up to 7 awards Direct costs are limited to \$250,000 per application	Unrestricted	http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-15-003.html

			GENETICS				
	Harnessing Genome Editing Technologies to Functionally Validate Genetic Variants in Substance Use Disorders (R21/R33)	RFA-DA-16-004	The purpose of this initiative is to harness genome or epigenome editing technologies to functionally validate and characterize genetic or epigenetic variants involved in substance use disorders. The purpose is also that the genetic resources generated will be made broadly available to the scientific community to probe more deeply into the neurobiological mechanisms involved in the function of a variant, gene, or pathway and provide critical foundational knowledge for the development of future prevention, diagnostic, and therapeutic strategies.	8/25/15	Est. Total Program Funding: \$2,000,000	Unrestricted	http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-16-004.html
	Behavioral Epigenomics of Aging in Twin Studies (U24) (HHS, NIH)	RFA-AG-16-007	The purpose of this FOA is to accelerate progress in behavioral genomics and aging via the establishment of a twin-epigenomic network that will facilitate collaboration between existing twin studies of aging, including work on the harmonization of phenotypes and (epi)genotype collection procedures as well as the development of statistical methods for the analysis and meta-analysis of data sets including genomic, epigenomic, gene expression, and behavioral phenotypic data. Larger scale support for the collection of samples suitable for epigenomic analysis in specific studies may be supported by other opportunities.	1/14/16	Award Ceiling: \$300,000 Estimated Total Funding: \$450,000	Unrestricted	http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-16-007.html

			IMAGING				
	Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24) (HHS, NIH)	PAR-15-266	The purpose of this FOA is to invite Cooperative Agreement (U24) applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve correlation of results for co-clinical trials. The scientific goals of this FOA are to: (a) perform the appropriate optimization of the pre-clinical quantitative imaging methods, (b) implement the optimized methods in the co-clinical trial, and finally (c) populate a web-accessible research resource with all the data, methods, workflow documentation, and results collected from the co-clinical investigations.	11/17/15	Award Ceiling: \$500,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-15-266.html
			KIDNEY				
	Adherence Studies in Adolescents with Chronic Kidney or Urologic Diseases (R01) (HHS, NIH)	RFA-DK-10-004	The purpose of this Funding Opportunity Announcement (FOA) is to support research to improve adherence in adolescents with chronic kidney or urologic diseases. Therefore, this Funding Opportunity Announcement (FOA) invites applications from new or established investigators to pursue research to better understand factors that influence adherence, develop appropriate measures of adherence, and test innovative strategies to enhance adherence in this vulnerable population.	11/2/15	Award Ceiling: \$450,000	Unrestricted	http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-15-017.html

			GENERAL				
Assay Validation For High Quality Markers For NCI-Supported Clinical Trials (Admin Supp)	PA-15-264	The purpose of this Funding Opportunity Announcement (FOA) is to improve the development and validation of molecular diagnostics for the treatment, control, or prevention of cancer. This FOA includes, but is not limited to, the validation of prognostic, predictive or response markers for treatment and markers for cancer control or prevention trials. Applicants should have an assay that works in human samples and whose importance is well justified for development into a clinical assay. In addition, analytical validation of assays for these markers should be achieved when the application is submitted so that clinical validation may be achieved with little further analytical validation needed.	7/8/18	Award Ceiling: \$150,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-15-264.html	
DoD Duchenne Muscular Dystrophy Translational Leverage Award	W81XWH-15-DMDRP-TLA	The DMDRP Translational Leverage Award (TLA) mechanism is being offered for the first time in FY15. The TLA supports leveraging existing human-based resources in translational research to address high-impact research ideas or unmet needs in at least one FY15 DMDRP Focus Area. Often, resources are not leveraged for maximum use beyond the original source, and as a result, investigators expend time and money to duplicate those resources. This award supports translational research projects leveraging and/or querying existing repositories, registries, and/or clinical trials or clinical studies in order to conduct research in the FY15 DMDRP Focus Areas. Projects may include, but are not limited to, drug and/or device development, novel interventions, resource refinement, database mining, and correlative studies.	Pre-application: 7/22/15 Full submission: 10/21/15	Est. Total Program Funding: \$400,000	Unrestricted	http://cdmrp.army.mil/funding/pa/15dmdrptla_pa.pdf	

	DoD Duchenne Muscular Dystrophy Investigator-Initiated Research Award	W81XW H-15-DMDRP-IIRA	The DMDRP Investigator-Initiated Research Award (IIRA) supports translational research that will accelerate the movement of promising ideas in DMD into clinical applications. Translational research may be defined as an integration of basic science and clinical observations with the specific goal of developing new therapies. While the ultimate goal of translational research is to move an observation forward into clinical application, translational research is most effective as a two-way continuum between the bench and the bedside. Within this continuum, the IIRA supports mid-stage or later translational research projects, including early-phase, proof-of-principle clinical trials and correlative studies to better inform the development of drugs, devices, and other interventions.	Pre-application: 7/22/15 Full Submission: 10/21/15	Est. Total Program Funding: \$2,000,000	Unrestricted	http://cdmnp.army.mil/funding/pa/15dmdrpiira_pa.pdf
	NINDS Exploratory Clinical Trials for Small Business (R42)	PAR-15-278	The purpose of this funding opportunity announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Technology Transfer (STTR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The projects must focus on products related to the mission and goals of the NINDS and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Only STTR Phase II and Fast-Track applications are supported under this program. STTR Phase I applications are only accepted as part of a Fast-track application.	4/5/18	Total Funding Support may Not Exceed: \$150,000 for Phase I; \$1,000,000 for Phase II	Small Businesses	http://grants.nih.gov/grants/guide/pa-files/PAR-15-278.html
	NINDS Exploratory Clinical Trials for Small Business (R44)	PAR-15-277	The purpose of this funding opportunity announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The projects must focus on products related to the mission and goals of the NINDS and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Only SBIR Phase II and Fast-Track	4/5/18	Total Funding Support may Not Exceed: \$150,000 for Phase I; \$1,000,000 for Phase II	Small Businesses	http://grants.nih.gov/grants/guide/pa-files/PAR-15-277.html

			applications are supported under this program. SBIR Phase I applications are only accepted as part of a Fast-track application.				
NIH Transformative Research Awards (R01)	RFA-RM-15-005	The NIH Transformative Research Awards complement NIH's traditional, investigator-initiated grant programs by supporting individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. Little or no preliminary data are expected. Projects must clearly demonstrate the potential to produce a major impact in a broad area of biomedical or behavioral research.	10/9/15	Total Funds Available: \$15 million	Unrestricted	http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-15-005.html	
Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]) (HHS, NIH)	PA-15-270 / PHS 2015-02	This NIH Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) Phase I, Phase II, Fast-Track, and Phase IIB Competing Renewal grant applications. The PHS 2015-2 SBIR/STTR Program Descriptions and Research Topics for NIH represent scientific program areas that may be of interest to applicant SBCs in the development of projects that have potential for commercialization.	Cycle I: 9/5/15 Cycle II: 1/5/16 Cycle III: 4/5/16	Total funding support (direct costs, indirect costs, fee) may not exceed \$150,000 for Phase I awards and \$1,000,000 for Phase II awards without Congressional approval.	Small businesses	http://grants.nih.gov/grants/guide/pa-files/PA-15-270.html	